CHARM - NCT02864953Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Please note, some trial-specific information on this page is sourced from clinicaltrials.gov.
About
Trial summary
TYPEInterventional
PHASE
Phase
Clinical trials are done in different phases (0-4). Each phase provides important information about the drug. If a drug does not pass a particular phase, it cannot progress to the next phase. Visit the About Clinical Trials page to learn more.
Phase 3
CONDITION
Brain Edema
Stroke, Acute
INTERVENTIONS
Interventions
The drug, device, or procedure being tested.
Drug:BIIB093
Administered as specified in the treatment arm.
Drug:Placebo
Administered as specified in the treatment arm.
ENROLLMENT
Enrollment
The number of participants needed to take part in this trial.
535 participants
(Actual)
18 Years to 85 Years
(Adult, Older Adult)
LOCATIONS250
Key dates
Key dates
When the trial is conducted - from the date the first participant is enrolled to the date of the last participants's final visit.
The results of this clinical trial may not be available, especially if the clinical trial has not completed.
We're committed to sharing information about our clinical research in alignment with global legal requirements, the industry trade association principles, and internal company policies. Generally, results summaries for clinical trials in approved products are available within one year of the trial completion. Please refer to Biogen's transparency & data sharing policy for more information.
Clinical trial registers
Clinical trial registers, like clinicaltrials.gov, provide information about registered clinical trials.
Publishing results for completed clinical trials on clinical trial registers help us share information about our clinical research. The results we publish here are written for healthcare professionals.
Please contact a clinical trial site directly to learn more about the trial. If no contact details are available, or for general inquiries, please contact the Biogen Clinical Trial Center.
